Copyright © AcuityBio Corporation 2018. All rights reserved.

Primary Contact: jschwartz@acuitybio.com 

Created by Brodly Inc. 

ABOUT

AcuityBio Corp.
 

AcuityBio was founded by Mark Grinstaff, Ph.D., Alain Hanover, M.S., Jesse Wolinsky, Ph.D., and John 'Jay' Schwartz, Ph.D. in late 2009 to commercialize novel polymer drug delivery technologies to treat various types early stage, soft tissue cancers. AcuityBio's lead product candidate aimed at preventing the recurrence of non-small cell lung cancer is based on a synthetic polymer technology invented by co-founders Professor Mark Grinstaff, Ph.D. and Jesse Wolinsky, Ph.D. at Boston University (BU), Departments of Biomedical Engineering and Chemistry. AcuityBio is a privately-held company based in the Greater Boston area.

 
Our Team
John 'Jay' Schwartz Ph.D
CEO

jschwartz@acuitybio.com 

Dr. Schwartz received his Ph.D. in Biochemistry and Molecular Biology at New York Medical College and was a Post-doctoral fellow at the M.I.T. Department of Biology / Harvard Medical School. He served as a lab head as Research Scientist Faculty at the M.I.T. Center for Biomedical Engineering. The CEO, Dr.Schwartz, was co-founder of engeneOS, Inc. a venture-backed bio-nanotechnology company with a highly successful exit through acquisition. Prior to joining AcuityBio, he was a consultant in his capacity as Director of Life Sciences at Stage1 Strategies, LLC, a strategy and management-consulting firm focused on assisting emerging technology and early-stage companies to develop, grow and achieve exits for investors through strategic acquisition with large pharmaceutical companies.

Karen English CPA MBA
CFO

karen@acuitybio.com 

Oded Biran
CBO

oded@acuitybio.com

Oded has established, managed and developed various functions at life Science companies. Experienced in operations, business strategy and corporate development, as well as business development and licensing. Prior to joining Acuity, Oded was the founder and CEO of Rok Diagnostics and served as a consultant to various companies, before which, he was Chief Legal Officer to Rosetta Genomics, a publicly traded biotechnology company. 

Karen brings to Acuity 15 years of accounting and operations management experience.  Karen served as interim CFO and as an Accounting Manager for two non-profit organizations. As a consultant, she developed systems which provided the management tools necessary to provide detailed financial reporting on a $200 million office/residential/retail project.

Her experience also includes forensic accounting, start-up infrastructure development, and creating financial models used in acquisition analyses and budgeting. She earned her Bachelor of Business Administration at University of Massachusetts, Amherst and her CPA while at KPMG Peat Marwick. Karen also holds an MBA from University of Massachusetts, Amherst